Distinguishing MG from Common Mimics

Welcome back to another NeurologyLive Peer Exchange series. In this episode titled, ‘Distinguishing MG From Common Mimics,’ the panel of experts examines the clinical and diagnostic features that help distinguish myasthenia gravis from other neurologic and neuromuscular conditions. The faculty highlight fluctuating and use-dependent muscle weakness as characteristic features of MG, including asymmetric ptosis, diplopia, bulbar symptoms, and proximal limb weakness. They contrast these patterns with those seen in conditions such as Guillain-Barré syndrome, Miller Fisher syndrome, Lambert-Eaton myasthenic syndrome, amyotrophic lateral sclerosis, toxic exposures, and progressive ophthalmoplegic disorders.

The discussion also explores the role and limitations of antibody testing. Expert faculty review testing for acetylcholine receptor, MuSK, and LRP4 antibodies and explain how seronegative disease, assay sensitivity, low-affinity antibodies, and false-positive findings can complicate diagnosis. They discuss circumstances in which repeat testing or cell-based assays may provide additional diagnostic information and emphasize the importance of interpreting serologic results in the context of clinical suspicion. The panel also cautions against overinterpreting antibodies that are not diagnostic of MG.

Ultimately, the experts reinforce that MG remains fundamentally a clinical diagnosis characterized by variable weakness that worsens with exertion and improves with rest, with serologic and electrophysiologic testing used to support and confirm the clinical assessment.

In the next episode, ‘Assessing the Quality-of-Life Burden of MG,’ panelists will continue their discussion on myasthenia gravis and highlight how disease severity, progression, functional impairment, comorbidities, and risk of crisis influence the urgency and intensity of treatment.